deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT00631449

Raltegravir Intensification in HIV-infected Patients

Raltegravir Intensification in Antiretroviral-treated Patients Exhibiting a Suboptimal CD4+ T Cell Response

Sponsor: Merck Sharp & Dohme LLC

Conditions HIV Infections
Interventions Placebo Raltegravir
Updated 11 times since 2017 Last updated: Aug 5, 2020 Started: Feb 29, 2008 Primary completion: Sep 30, 2009 Completion: Mar 31, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates HIV Infections and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 11 recorded versions since 2008 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Dec 2019 · 18 months · monthly snapshotCompleted~Dec 2019 – ~Sep 2020 · 9 months · monthly snapshotCompleted~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotCompleted~Jan 2021 – ~Jun 2022 · 17 months · monthly snapshotCompleted~Jun 2022 – ~Dec 2022 · 6 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE4

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE4

  5. Jun 2022 — Dec 2022 [monthly]

    Completed PHASE4

▶ Show 6 earlier versions

  1. Jan 2021 — Jun 2022 [monthly]

    Completed PHASE4

  2. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE4

  3. Dec 2019 — Sep 2020 [monthly]

    Completed PHASE4

  4. Jun 2018 — Dec 2019 [monthly]

    Completed PHASE4

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE4

  6. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • University of California, San Francisco
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations